Ovarian Cancer

Optimal dose suggested for dasatinib in ovarian cancer

(HealthDay)—A phase I trial of dasatinib combined with paclitaxel and carboplatin has determined the optimal dose of dasatinib and suggested some efficacy in women with advanced or recurrent ovarian cancer, ...

Nov 19, 2012
popularity 5 / 5 (1) | comments 0

Latest Spotlight News

New compounds reduce debilitating inflammation

Six Case Western Reserve scientists are part of an international team that has discovered two compounds that show promise in decreasing inflammation associated with diseases such as ulcerative colitis, arthritis and multiple ...